Sigyn Therapeutics, Inc., a developer of dialysis-like therapies targeting cardiovascular disease and cancer, has outlined strategic initiatives including a potential merger and asset sale to address financial constraints stemming from its inability to uplist to the Nasdaq exchange. The company's CEO, Jim Joyce, detailed these plans in a shareholder update, emphasizing efforts to advance therapies while minimizing shareholder dilution.
The company's lead candidate, CardioDialysis, is designed to address cardiovascular disease by reducing cholesterol-transporting lipoproteins and inflammatory molecules. Joyce noted that lipoprotein apheresis devices, which reduce similar lipoproteins, demonstrate greater reduction in major adverse cardiovascular events than drugs, but are limited to fewer than 60 specialized centers in the U.S. CardioDialysis is intended for use on existing dialysis machines at over 7,500 U.S. clinics, potentially broadening access.
CardioDialysis also shows promise for sepsis, a leading cause of in-hospital mortality with no approved therapy. The device has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators. Joyce referenced the PMX hemoadsorption device by Spectral Medical, a company with a market value of approximately $300 million, which targets endotoxin removal and is undergoing clinical studies. He encouraged following Spectral Medical's progress at https://www.spectralmedical.com.
In vitro studies suggest CardioDialysis may also benefit traumatic brain injury by reducing systemic inflammation, an indication now considered a valuable asset for potential strategic transactions. Joyce highlighted his prior experience at Aethlon Medical, where he oversaw development of the Hemopurifier, which received FDA Breakthrough Device designations and was named a top invention by TIME magazine.
Sigyn's current challenges stem from its status as an OTC-traded company. Joyce explained that a planned uplist to Nasdaq failed due to regulatory hurdles: Nasdaq requested investor approval before SEC deemed the registration statement effective, while SEC sought contingent listing approval from Nasdaq beforehand. This impasse led to withdrawal of the registration statement, impacting the company's ability to raise capital without diluting shareholder value.
To navigate forward, Sigyn is considering a merger with a Nasdaq-listed company at risk of not meeting the upcoming $5 million minimum market value of listed securities requirement. The company also plans asset sales, as detailed in a January 15 shareholder update available at https://www.sigyntherapeutics.com/investors/news-events/press-releases/detail/118/sigyn-therapeutics-issues-shareholder-update-highlighting. Joyce emphasized that share price and exchange do not affect the therapies' potential but impact financing capabilities.
The company's pipeline includes ImmunePrep for cancer immunotherapy, ChemoPrep for targeted chemotherapy delivery, and ChemoPure to reduce chemotherapy toxicity. Sigyn had 2,330,042 shares outstanding as of March 11, 2026. The strategic moves aim to sustain development of therapies addressing leading causes of death worldwide, including cardiovascular disease and sepsis, while stabilizing the company's financial footing.
